DF 7001
Alternative Names: DF-7001Latest Information Update: 08 Mar 2024
At a glance
- Originator Dragonfly Therapeutics
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours